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Objective: Both rare copy number variants (CNVs) and common single-nucleotide 
polymorphisms (SNPs) contribute to liability to schizophrenia, but their etiological 
relationship has not been fully elucidated. The authors evaluated an additive model 
whereby risk of schizophrenia requires less contribution from common SNPs in the presence 
of a rare CNV, and tested for interactions. 
 
Method: Genetic data from 21,094 case subjects with schizophrenia and 20,227 control 
subjects from the Psychiatric Genomics Consortium were examined. Three classes of rare 
CNVs were assessed: CNVs previously associated with schizophrenia, CNVs with large 
deletions ≥500 kb, and total CNV burden. The mean polygenic risk scores (PRSs) between 
study subjects with and without rare CNVs were compared, and joint effects of PRS and 
CNVs on schizophrenia liability were modeled by using logistic regression. 
 
Results: Schizophrenia case subjects carrying risk CNVs had a lower polygenic risk than case 
subjects without risk CNVs but a higher risk than control subjects. For case subjects carrying 
known risk CNVs, the PRS was diminished in proportion to the effect size of the CNV. The 
strongly associated 22q11.2 deletion required little added PRS to produce schizophrenia. 
Large deletions and increased CNV burden were also associated with lower polygenic risk in 
schizophrenia case subjects but not in control subjects or after removal of known risk CNV 
carriers. 
 
Conclusions: The authors found evidence for interactive effects of PRS and previously 
associated CNVs for risk for schizophrenia, and the results for large deletions and total CNV 
burden support an additive model. These findings offer insights into the genetic architecture 
of schizophrenia by illuminating how different established genetic risk factors act and 
interact to influence liability to schizophrenia. 
 
Schizophrenia is a serious, chronic mental illness with high heritability (64%281%) (1, 2). 
Important progress has been made in understanding the genetic basis of schizophrenia. 
Genome-wide association studies (GWAS) have identified more than 108 single-nucleotide 
polymorphisms (SNPs) that contribute to increased likelihood of schizophrenia (3). However, 
the majority of SNPs contributing to schizophrenia liability fall short of genome-wide 
significance, and indices of polygenic risk incorporating larger proportions of SNPs have 
consistently demonstrated highly significant case-control differences (3, 4). 
 
Although common SNPs have weak individual effects (odds ratios,,1.2), several rare copy 
number variants (CNVs) have been identified that have a much stronger impact on risk 
(odds ratios, 2–57) (5). Furthermore, an increased liability to schizophrenia has been 
associated with large deletions throughout the genome (6, 7) and with an elevated overall 
CNV burden (7–9). For the specific deletions and duplications that confer risk for 
schizophrenia, only 1.4%2 2.5% of individuals with schizophrenia carry one of them (5). 
Risk for schizophrenia conferred by these CNVs is not deterministic, and many carriers do 
not develop schizophrenia. It is not known whether the additional factors affecting disease 
liability are environmental or reflect genetic variation within the CNV region or risk variants 
elsewhere in the genome. 
 
Despite the strong effects from individual CNVs, the aggregate effect of common SNPs are 
at least an order of magnitude greater (7, 10). Some overlap between GWAS and CNV 
findings for schizophrenia has been reported (3, 7), and case subjects with associated CNVs 
have been shown to have elevated liability from common SNPs (11). However, these two 
categories of genetic risk have generally been examined separately, and the relationship 
between them remains poorly understood. 
 
In this study, we investigated the ways in which common SNPs and rare CNVs jointly 
contribute to the risk for schizophrenia. We tested a liability threshold model in which 
SNPs and CNVs act additively to confer disease risk. This model predicts that individuals with 
schizophrenia who have large-effect CNVs will, on average, have a smaller contribution from 
common SNPs. We also tested for interactions between common SNPs and specific CNVs. A 
second testable prediction from this model was that among control subjects, those with 
large-effect CNVs would typically have lower polygenic risk than control subjects without 
CNVs. 
 
METHOD 
Participants 
We examined individuals from the Psychiatric Genomics 
Consortium schizophrenia study (3) with available CNV data. Genome-wide genotype data 
from 33 independent European ancestry case-control samples were used (for further 
details, see Table S1 in the online supplement). Each sample collection was approved by the 
relevant ethical review boards. All participants were at least 18 years old and provided 
written informed consent. 
 
CNV Data 
CNV data were derived from GWAS arrays and processed using a standardized pipeline by 
the Psychiatric Genomics Consortium CNV analysis group (for further details, see Marshall et 
al. [12]). Briefly, multiple calling algorithms were applied to raw Illumina or Affymetrix 
intensity data from each individual. A consensus CNV call data set was generated by 
merging data at the sample level. After merging, arrays with excessive probe variance or 
guanine-cytosine bias were removed, as were samples with mismatches in sex, ancestry 
outliers, >7 Mb total CNV burden, or chromosomal aneuploidies. We removed samples with 
low-quality SNP genotyping and samples from individuals who were related to any other 
study subject. The final data set of rare, high quality CNVs retained CNVs ≥20 kb, ≥10 
probes, and frequency <0.01. CNVs that overlapped >50% with regions tagged as copy 
number polymorphic on any platform were excluded. Only autosomal chromosomes were 
used to facilitate comparability between sexes. 
A total of 41,310 individuals met the above criteria (schizophrenia case subjects, N=21,088; 
control subjects, N=20,222). 
 
Risk CNV Classes 
Three categories of CNV risk were investigated. First, implicated loci were specific CNVs 
reported as genome-wide significant (for further details, see Table S2 in the online 
supplement). Carriers were defined as having ≥50% reciprocal overlap with reported CNVs 
(study subjects with overlap <50% were excluded from all analyses involving implicated 
loci). For NRXN1 deletions, each exon was considered separately. Six study subjects carried 
two implicated CNVs, and the CNV conferring the greatest risk was retained for analysis. 
Second, large CNV deletions (≥500 kb) anywhere in the genome were carried by 722 case 
subjects and 477 control subjects. Third, the total CNV burden for each study subject was 
examined. 
 
Polygenic Risk Quantification 
We generated risk profile scores by weighting each SNP by its log odds ratio in an 
independent set of GWAS results and applying these weights to SNPs in a second target data 
set. Summed across all SNPs, this yields a risk score for each study subject. These scores are 
a continuous and normally distributed measure of schizophrenia liability with highly 
significant differences between case and control subjects (4, 3). 
Risk profile scores were generated by conducting leave one-out analyses (for further details, 
see the online supplement and reference 3). Briefly, low frequency (<10%) and low-quality 
(imputation INFO <0.9) indels and SNPs in the extended major histocompatibility complex 
region (chr6: 25–34 Mb) were excluded. We removed SNPs in high linkage disequilibrium 
and performed “clumping” (i.e., discarding variants within 500 kb and with r2 ≥0.1 with a 
more significantly associated SNP). Polygenic scoring was performed using PLINK (13) for 
multiple p-value thresholds ( , , 0.001, 0.01, 0.05, 0.1, 0.2, 0.5, and 1.0), 
multiplying the logistic regression weighting (i.e., the natural log of the odds ratio) of each 
variant by the imputation probability for the risk allele in each individual. The resulting 
values were summed over each individual to provide a whole genome risk profile score for 
further analysis. 
Scores were then normalized to reduce between-cohort variation (for further details, see 
the supplemental data and Figure S1 in the online supplement). The information contained 
in the normalized scores was concentrated through principal component analysis (see the 
online supplement). The first principal component (polygenic risk score 1 [PRS1]) explains 
69% of the total variability in the scores (see Figure S2A in the online supplement), was the 
only component associated with schizophrenia risk (odds ratio=2.40 [see Figure S2B in the 
online supplement]), and was used to index polygenic risk. This has the advantage of 
capturing the majority of polygenic risk in a single variable. 
 
Statistical Models and Hypotheses 
Intuitively, if the contributions of PRS1 level and CNVs to the risk of schizophrenia summed, 
we expected lower PSR1 levels among case subjects carrying CNVs compared with non 
carrier case subjects. In the presence of CNV-mediated risk, a lower PSR1 would be 
sufficient to place case subjects over the threshold for schizophrenia. A similar argument 
holds for control subjects, whereby control subjects with CNVs and high PRS1 levels would 
be underrepresented compared with control subjects without CNVs. 
More formally stated, since PRS1 and CNV status are both positively associated with the risk 
of schizophrenia, we hypothesized that an additive liability model with an increasing link 
function would predict lower PRS1 values for individuals strongly influenced by the presence 
of a previously associated 
 
 
 
CNV, a large deletion, or high total CNV burden. Because this prediction holds for both case 
and control subjects separately, we were able to test the following core hypotheses: 1) for 
schizophrenia case subjects, the mean PRS1 among CNV carriers and individuals with higher 
total CNV burden would be lower than that for noncarriers and individuals with lower total 
CNV burden, and 2) for control subjects, the mean PRS1 among CNV carriers and individuals 
with higher total CNV burden would be lower than that for noncarriers and individuals with 
lower total CNV burden. 
Both hypotheses were tested with respect to three CNV measures, although power was 
limited for testing in the control group because of the rarity of schizophrenia-associated 
CNV variants. For specific CNVs and large deletions, we tested differences in mean PRS1 
levels between carriers and noncarriers using a two-sided Welch t test. For total CNV 
burden, we regressed PRS1 levels on total CNV burden and used a two-sided Wald t test to 
test for negative slopes among case and control subjects. 
On the basis of our findings, we also fitted logistic regression models with schizophrenia 
status as outcome, PRS1 and CNV status as predictors, and adjustment for site, sex, CNV 
quality, and five ancestry principal components. 
These models were fitted separately for carriers and noncarriers of specific CNVs. By 
comparing a series of nested models via likelihood ratio tests and measures of model fit, we 
could quantify the contribution of PRS1 and CNV both individually and jointly as well as test 
for nonadditive effects in modeling schizophrenia risk (for further details, see the online 
supplement). For models with statistically significant nonadditive effects, we report 
predicted odds ratios to demonstrate the pattern of nonadditivity. 
 
 
 
RESULTS 
The numbers of case and control subjects carrying each type of risk CNV are presented in 
Table 1. Among case subjects, the mean polygenic risk score for CNV carriers was 
significantly lower than that for noncarriers (carrier group: PRS1=0.70; noncarrier group: 
PRS1=0.97; p=0.03) (Table 2). This relationship was stronger with increasing risk from the 
specific CNVs. When the CNVs were divided into three groups based on the odds ratio of 
their association with schizophrenia (odds ratio ranges <5, 5–15, and >15), only the carriers 
of CNVs with odds ratios >15 had a significantly lower PRS1 score than the noncarriers 
(Table 2). The relationship for individual CNVs is illustrated in Figure 1. On average, the 
mean PRS1 value for carriers of an individual CNV decreased with the effect size (odds ratio) 
of the CNV. For example, we found that whereas case subjects with 15q11.2 deletions (odds 
ratio=2.2) (5) had a mean PRS1 close to what we observed for noncarrier case subjects, case 
subjects with 22q11.2 or 3q29 deletions (odds ratios, 28.3  and 57.7, respectively) (5) 
had much lower PRS1 scores (Figure 1) (see also Table S3 in the online supplement).  
For control subjects, the relationship was unexpectedly reversed, because carriers of CNVs 
with larger effect sizes had significantly higher mean risk scores (Table 2). Statistical 
significance and effect size were less clearly tied to reported odds ratios for control subjects 
than for case subjects. 
Case subjects with large-deletion CNVs had reduced PRS1 compared with noncarrier case 
subjects (PRS1=0.77 compared with PRS1=0.98, p=0.02). However, upon removal of case 
subjects carrying CNVs previously implicated to increase the risk for schizophrenia, the 
results became nonsignificant (PRS1=0.89 compared with PRS1=0.98, p=0.43). No 
statistically significant differences were observed for control subjects (Table 3). 
 
 
 
 
Increasing the total CNV burden was associated with significantly decreased PRS1 among 
case subjects (reduction ofmean PRS1 by 1.05 for each 10-kb extraCNV, p=0.0024) but not 
control subjects (increased mean PRS1 by 0.19, p=0.65) (Table 4). When the CNVs previously 
implicated in schizophrenia risk were removed, the burden of the remaining CNVs was not 
significantly associated with PRS1 (p=0.08). 
 
Model-Fitting Results 
For noncarriers of CNVs previously shown to be associated with schizophrenia, PRS1, large 
deletions, and total CNVs were individually significant (models 1–3) (for further details, see 
Table S4 in the online supplement). Both large deletions and total burden add significantly 
in an additive manner to PRS (models 4 and 5), with no indication of significant interactions 
(models 6 and 7). 
 
 
For carriers of these previously associated CNVs, the genetic risk score and the log(odds 
ratio) of the specific CNV as well as other large deletions had significant predictive power 
(models 1–3) but not total burden (model 4) (for further details, see Table S4 in the online 
supplement). Adding the log(odds ratio) to PRS1 improved the model significantly (model 5), 
and there was a significant interaction (that is, a nonadditive effect) between PRS1 and 
log(odds ratio) (model 7). Similarly, adding large deletions to PRS1 conferred significant 
improvement (model 6), and there was a significant interaction between them (model 8). 
The interaction parameter was negative in both models 7 and 8, meaning that increasing 
PRS1 levels had less impact on the risk of schizophrenia in carriers of a specific CNV 
compared with noncarriers. However, once the PRS, the CNV effect size, and their 
interaction were properly accounted for, large deletions conferred no improvement (model 
9). 
The interaction between PRS1 and effect sizes for individual CNVs (model 7) is summarized 
in Table 5 (see also Table S4 in the online supplement). We report the predicted odds ratio 
for schizophrenia associated with an increase of PRS1 by one unit, sorted by the reported 
effect sizeof the individualCNVs (smallest to largest) (seeTableS2in the online supplement). 
We also included the corresponding predicted odds ratio for noncarriers (based on model 1) 
as a reference (see Table S4 in the online supplement). Only for carriers of the three CNVs 
with the lowest reported effect sizes (15q11.2 deletions, 16p13.11 duplications, and 1q21.1 
duplications) did we observe statistically significant evidence that an increase in the PRS 
actually increased the risk of schizophrenia (all variants, p ). The associated 
predicted odds ratios (1.41–1.56) were slightly in excess of the predicted odds ratio for 
noncarriers (1.40), although not statistically significantly (all variants, p>0.11). 
Crucially, the results for the interaction model for specific loci are in line with the results of 
testing the original two hypotheses for this CNV category: because of the smaller 
contribution of PRS1 to the total risk of schizophrenia among carriers of medium-risk to 
high-risk loci, the model implies that case subjects who carry a specific CNV with higher 
reported risk would have a lower mean PRS1 compared with case subjects who do not. 
 
 
DISCUSSION 
The goal of this study was to clarify how aggregate measures of common risk SNPs and rare 
CNVs jointly contribute to the risk for schizophrenia. Five results were noteworthy. First, as 
predicted by an additive model, aggregate affected carriers of previously identified CNVs for 
schizophrenia had significantly lower PRSs than affected noncarriers. Second, when we 
subdivided these CNVs by effect size, the significant reduction of PRS was only seen for the 
CNVs with the strongest effect on schizophrenia risk. Third, while all case subjects with large 
deletions cumulatively had a significantly lowered PRS, when we eliminated case subjects 
with previously implicated CNVs, this effect disappeared. Fourth, the total CNV burden 
among case subjects was significantly and inversely related to the PRS. The effect was 
entirely the result of deletions, whereas duplications had no effect. Furthermore, as with 
the large deletions, when we removed case subjects with known CNVs, this relationship 
disappeared.  Finally, our formal modeling revealed an additive relationship between the 
PRS and either total CNV burden or large CNVs, meaning that the risk for schizophrenia was 
well captured by simply taking the sum of these two kinds of genetic risks. However, when 
we examined individual CNVs, we found a more complex relationship: increasing PRS levels 
had less influence on the risk of schizophrenia among carriers of large effect CNVs compared 
with carriers of small- to moderate effect CNVs. 
Our results are congruent with a previous report that specific previously associated CNVs 
require a genomic context of liability to result in schizophrenia (11), supporting the 
conclusion that these loci do not represent fully penetrant Mendelian forms of illness. Our 
analyses of 41,321 individuals included the 11,428 study subjects previously reported. 
And in addition to establishing more conclusively that carriers of schizophrenia-associated 
CNVs generally require elevated genomic risk, we tested and confirmed that these forms of 
genetic risk act in an interactive manner. Additionally, we were able in this study to evaluate 
individual CNV-PRS relationships, yielding important results for carriers as well as 
researchers generating disease models involving these CNVs. Furthermore, this study tested 
relationships between polygenic risk and other well-replicated categories of CNVs causing 
risk, large deletions throughout the genome, and total CNV burden. 
 
For large-deletion carriers and high total CNV burden, the lower PRS1 observed in case 
subjects was primarily driven by carriers of the implicated CNVs and was not mirrored in the 
results for healthy control subjects. This may have been due to the genomic locations of 
these CNVs in the two study groups, because the case subjects more often carried CNVs 
intersecting regions of genomic risk for schizophrenia. Furthermore, schizophrenia case 
subjects comprised only a small portion of one tail of the liability distribution. Therefore, a 
small elevation in risk from CNVs in control subjects was not likely to have a detectable 
effect at most points along the liability curve. These results also suggest that the specific 
CNVs conferring substantial risk for schizophrenia have likely all been identified. 
The only results inconsistent with our original hypotheses was the observation of greater 
polygenic loading in control subjects with any previously implicated CNV compared with 
noncarrier control subjects. Data on the ages for the control subjects were not available; 
many of them may have been young and still within the age at risk. Also, not all samples 
used screened control subjects; some could have had schizophrenia or developed 
schizophrenia later, contributing to the observed results. Because both CNV and polygenic 
risk could drive behavioral characteristics in a similar direction, assortative mating could 
produce coaggregation, but not specifically in control subjects. This would be more likely in 
carriers of the low-effect-size CNVs, which are more often inherited. 
Different patterns of results may exist across diseases, indicating different genetic 
architectures. However, one investigation of children with attention deficit hyperactivity 
disorder (ADHD) found a similar pattern (15). ADHD case subjects with large deletions (>500 
kb) (N=60) had lower ADHD PRSs compared with other affected children (N=421) Additional 
studies of other complex genetic diseases could offer a broader understanding of the range 
of genetic architectures underlying neuropsychiatric disorders. 
Six potential limitations should be considered in the interpretation of our results. First, even 
in this study, involving, to our knowledge, the largest number of schizophrenia case subjects 
to date with CNV data, power to detect effects in the carriers of the specific risk CNVs was 
limited by their rarity. Second, rare single-nucleotide variants identified through DNA 
sequencing comprise a third class of genetic variation contributing to schizophrenia risk 
(10). Such data were not available for the samples analysed and therefore were not 
incorporated into these analyses. Third, copy number polymorphisms with >1% frequency, 
which are rarely investigated, were not examined. Fourth, although we tested interactions 
between CNVs and aggregate SNPs, epistatic interactions may exist between specific 
CNVs and specific risk SNPs that are beyond the scope of this study. Fifth, SNPs included in 
the polygenic scoring falling within the previously associated CNV regions could have biased 
analyses of interactions. Because only 399 of 102,636 SNPs fell in these loci, this is unlikely 
to have influenced our results. Finally, carriers of some implicated CNVs (particularly 
22q11.2) who do not develop schizophrenia are unlikely to be recruited as control subjects, 
because of medical problems or intellectual impairment. This may produce inflated 
estimates of schizophrenia risk and complicates interpretation of the relationship between 
CNV effect sizes and genomic risk. We therefore conservatively used the lower-bound 
estimate of the 22q11.2 effect size. It is noteworthy that in a previous sample of 329 carriers 
of this deletion, those who developed schizophrenia were significantly more likely to have 
additional CNVs affecting genes relevant to this disorder (16). 
 
CONCLUSIONS 
Genetic risk from rare CNVs and common SNPs contributes to liability to schizophrenia. 
Previously implicated CNVs (individually and in aggregate), large CNV deletions, and total 
genomic CNV burden were separately compared against aggregated genomic risk from 
SNPs. Schizophrenia case subjects carrying risk CNVs had lower polygenic risk compared 
with other case subjects but higher risk compared with control subjects. When these risk 
CNVs were categorized by their effect size on schizophrenia, lower polygenic risk was 
observed clearly only in those with the largest effect sizes. Our results also support 
interactions for PRS and the implicated CNVs and an additive model for the other 
CNV classes. Comprehensive understanding of schizophrenia etiology should incorporate 
risk measures from different genomic sources, and the integration of sequencing-derived 
rare variation and environmental influences along with CNVs and common genetic variation 
could ultimately offer a more complete picture. 
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